Cargando…
Patients with Type 2 Diabetes Mellitus failing on oral agents and starting once daily insulin regimen; a small randomized study investigating effects of adding vildagliptin
BACKGROUND: The addition of a DDP4-inhibitor to existing insulin therapy reduces HbA1c. However, no data exist about the addition of these agents at the beginning of insulin treatment in type 2 diabetes while this could especially be interesting because it is during this period that considerable res...
Autores principales: | de Ranitz-Greven, Wendela Lucia, Beulens, Joline Wilhelma Johanna, Hoeks, Lette Birgit Elisabeth Anne, Belle-van Meerkerk, Gerdien, Biesma, Douwe Hedde, de Valk, Harold Wessel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161897/ https://www.ncbi.nlm.nih.gov/pubmed/25175981 http://dx.doi.org/10.1186/1756-0500-7-579 |
Ejemplares similares
-
The prevalence of vascular and metabolic complications after lung transplant in people with cystic fibrosis in a Dutch cohort
por: Oppelaar, Lisa M., et al.
Publicado: (2023) -
The long-term effect of mTOR inhibition on lipid and glucose metabolism in tuberous sclerosis complex: data from the Dutch TSC registry
por: Mulder, Femke V. M., et al.
Publicado: (2022) -
External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease
por: Smidt, Lisanne C. A., et al.
Publicado: (2021) -
Epilepsy, impaired functioning, and quality of life in patients with tuberous sclerosis complex
por: Vergeer, Menno, et al.
Publicado: (2019) -
Pretransplant HRCT Characteristics Are Associated with Worse Outcome of Lung Transplantation for Cystic Fibrosis Patients
por: Belle-van Meerkerk, Gerdien, et al.
Publicado: (2015)